Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2019

01-07-2019 | Breast Cancer | Correction

Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer

Authors: Jangsoon Lee, Bora Lim, Troy Pearson, Kuicheon Choi, Jon A. Fuson, Chandra Bartholomeusz, Linda J. Paradiso, Thomas Myers, Debu Tripathy, Naoto T. Ueno

Published in: Breast Cancer Research and Treatment | Issue 1/2019

Login to get access

Excerpt

Unfortunately in the original publication of the article, the author’s funding support has been mentioned incorrectly. The correct funding statement should read as “This work was supported by the Morgan Welch Inflammatory Breast Cancer Research Program, the State of Texas Rare and Aggressive Breast Cancer Research Program, MD Anderson’s Cancer Center Support Grant (P30CA016672, used the Characterized Cell Line Core Facility and Flow Cytometry and Cellular Imaging Facility), and Spirita Oncology, LLC.” …
Metadata
Title
Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer
Authors
Jangsoon Lee
Bora Lim
Troy Pearson
Kuicheon Choi
Jon A. Fuson
Chandra Bartholomeusz
Linda J. Paradiso
Thomas Myers
Debu Tripathy
Naoto T. Ueno
Publication date
01-07-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05218-8

Other articles of this Issue 1/2019

Breast Cancer Research and Treatment 1/2019 Go to the issue

Epidemiology

Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1)

Clinical trial

GEC-ESTRO APBI classification as a decision-making tool for the management of 2nd ipsilateral breast tumor event

Review

The relation between stressful life events and breast cancer: a systematic review and meta-analysis of cohort studies

Preclinical study

Breast cancer research and treatment reconstruction of unilateral breast structure using three-dimensional ultrasound imaging to assess breast neoplasm

Epidemiology

Plasma B-vitamins and one-carbon metabolites and the risk of breast cancer in younger women

Clinical trial

Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits